ArticleFrontiers in immunology2026

Unlocking HER2 as a target in KRAS-mutated rectal cancer: a case of significant response to zanidatamab-based regimen.

Kexun Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.